Bone, joint, and mobility is the main area connected here, and any felt benefit should be read together with the human evidence base.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Paper IDs and full lists are private. Only study types and summaries are shown.
In patients with knee OA with at least moderate subjective improvement with prior glucosamine use, this study provides no evidence of symptomatic benefit from continued use of glucosamines sulfate.
Chs3p-dependent chitin synthesis in S. cerevisiae is regulated both by the levels of intermediates of the UDP-GlcNAc biosynthetic pathway and by an increase in the activity of the enzyme in the plasma membrane.
Circuit style resistance-training and weight loss improved functional capacity in women with knee OA and functional aerobic capacity was increased to a greater degree for those in the HP and GCM groups while there were some trends suggesting that supplementati
To determine the short‐term efficacy of oral glucosamine supplementation by evaluating structural lesions in the knee joints, as assessed using 3T magnetic resonance imaging (MRI).
GS 1500 mg QD PO for 12 weeks was associated with statistically significant reductions in pain and improvements in functioning, with decreased analgesic consumption, compared with baseline and placebo in these patients with knee OA.
In people with hip or knee OA, walking a minimum of 3000 steps, at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms.